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creativecommons.org/changes in memory in the absence of objective impairment in memory. However, it is not fully known
whether persons with SMCs harbor brain alterations related to Alzheimer’s disease (AD) or whether
they indeed demonstrate poorer cognitive performance.
Methods: The participants were 261 middle-age adults (mean age 54.30 years) enrolled in the
Wisconsin Registry for Alzheimer’s Prevention, a registry of cognitively normal adults at risk of
AD. They answered a question pertaining to subjective memory, completed a comprehensive neu-
ropsychological examination, and subsequently underwent a volumetric magnetic resonance imag-
ing scan. Cortical thickness measurements were derived from 10 a priori regions of interest
involved in AD. Analyses of covariance were conducted to investigate the group differences in
cortical thickness and neuropsychological measures.
Results: Compared with individuals without SMCs, those with SMCs had significant cortical
thinning in the entorhinal, fusiform, posterior cingulate, and inferior parietal cortices and
significantly reduced amygdala volume. Similarly, those with SMCs had significantly lower
test scores on measures of Immediate Memory, Verbal Learning & Memory, and Verbal Abil-
ity. Additional adjustment for depressive symptoms (which differed between the groups)
attenuated only the findings for the entorhinal cortex (P 5 .061) and Verbal Ability
(P 5 .076).
Conclusion: At-risk, cognitively healthy individuals with SMCs exhibit cortical thinning in brain re-
gions affected by AD and poorer performance on objectivememory tests. These findings suggest that,
in some individuals, SMCs might represent the earliest stages of AD.
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Recent years havewitnessed an increasing interest in sub-
jective memory complaints (SMCs) as a potential precursor
to symptomatic Alzheimer’s disease (AD). Although
currently no definition has been universally accepted [1],his is an open access article under the CC BY-NC-ND license (http://
Table 1
Background characteristics of study participants
Variable SMC1 (n 5 77) SMC2 (n 5 184) P value
FH positive (%) 77.9 68.5 .124
APOE4 positive (%) 46.8 40.2 .329
Female sex (%) 67.5 67.4 .982
White race (%) 94.8 96.2 .610
Age (y) .925
Mean 6 SD 54.33 6 6.10 54.416 6.44
Range 41.89–66.40 40.31–67.56
Education (y) .763
Mean 6 SD 15.97 6 2.25 16.16 6 2.33
Range 12–20 12–22
MMSE score .707
Mean 6 SD 29.43 6 0.80 29.53 6 0.88
Range 27–30 25–30
CES-D score 16 14.5 2.7 , .001
Interval between WRAP
visit and MRI (y)
.750
Mean 6 SD 5.37 6 1.87 5.52 6 1.81
Range 0.00–9.00 0.00–9.54
Abbreviations: FH, parental family history of Alzheimer’s disease;
APOE4, varepsilon 4 allele of apolipoprotein E gene; MMSE, Mini Mental
State Examination; CES-D, Center for Epidemiological Studies Depression
Scale (16 is the established cutpoint for elevated depressive symptoms [31]);
MRI, magnetic resonance imaging; SMC, subjective memory complaint;
WRAP, Wisconsin Registry for Alzheimer’s Prevention.
NOTE. All measurements were taken from the baseline visit, except for
the MMSE, which was first given at the Wave 2 visit (approximately 4 years
after baseline).
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memory that fall below the detection thresholds of common
cognitive tests [1]. Furthermore, the question of whether
individuals with SMCs are a population with an increased
risk of progression to AD remains controversial. Some in-
vestigators have suggested that SMCs are characteristic of
a “worried well” population; hence, the lack of an associa-
tion between SMCs and memory performance in such
studies [2,3]. In contrast, others have found significant
relationships between SMCs and objective cognitive
performance [4–6]. For example, a recent study [5], found
significant correlations between SMCs and decreased per-
formance on objective measures of episodic memory, work-
ing memory, and semantic knowledge. In addition,
longitudinal studies have shown SMC groups to have a faster
rate of decline on immediate recall and related psychometric
measures [4,7].
If SMCs represent an individual’s awareness of early,
subtle, changes in cognition, a relationship should be ex-
pected between the presence of SMCs and specific AD path-
ologic processes, such as atrophy of the medial temporal
lobes and lateral/middle parietal cortices [8–11]. To date, a
number of studies have reported evidence for such brain
changes. For example, Jessen et al [12] found a decreased
entorhinal cortex volume in individuals with SMCs
compared with healthy controls. Additionally, a more recent
study [13] found gray matter volume reductions in several
brain areas, such as the hippocampus, anterior cingulate,
and precuneus in elderly subjects with SMCs. Other studies
probing additional known AD biomarkers have found that
SMCs are associated with higher amyloid-b deposition
[5,14,15]. Taken together, these findings suggest that the
memory complaints could reflect actual AD-related brain al-
terations.
Although brain volume might shrink as a result of either
normal aging or a neurodegenerative process such as AD,
cortical thinning is believed to be a hallmark feature of
AD [16,17]. However, some have reported thinning in the
prefrontal cortex as a part of the nonpathologic aging
process [18,19]. Although previous studies have examined
the relationship between regional brain volume and
SMCs, no studies to date have investigated whether SMCs
are linked to thinning in AD-sensitive brain regions.
Furthermore, most of the studies in this area have focused
on cohorts of elderly adults. Thus, it remains unknown
whether SMCs in midlife is related to brain and cognitive
changes, particularly in an at-risk cohort that might osten-
sibly be overly sensitive to normal fluctuations in mental
function.
Accordingly, in the present study, we examined whether
SMCs are associated with thinning of cortical regions
involved in AD within a middle-age cohort of cognitively
normal individuals with risk factors for AD. Additionally,
we also examined how individuals with SMCs perform on
objective cognitive tests compared with those without
SMCs.2. Methods
2.1. Participants
The data from 261 middle-age adults from the Wisconsin
Registry for Alzheimer’s Prevention (WRAP) cohort were
used in the present study. WRAP is a longitudinal registry
composed of more than 1500 cognitively normal middle-
age adults aged 40 to 65 years at study entry [20]. The par-
ticipants for the present study were selected on the basis of
having completed a baseline WRAP visit and a subsequent
magnetic resonance imaging (MRI) scan. The sample was
enriched for a parental family history of AD (FH; 71.3%)
and possession of the ε4 allele of the apolipoprotein E
gene (APOE4; 42.1%). The methods for determining FH
have been described previously [21]. In brief, to verify the
diagnosis of AD in the parent, the parental medical records
were obtained (including autopsy reports when available)
and reviewed by a multidisciplinary diagnostic consensus
panel. When these records were not available, the dementia
questionnaire [22] was used. The absence of an FH of AD
was verified through detailed medical history surveys and
telephone interview (including the dementia questionnaire)
with the participants. The inclusion in the FH group required
that the father had survived to at least age 70 years and the
mother to age 75 years, without incurring a formal diagnosis
of dementia or exhibiting cognitive deterioration. Women
comprised 67.4% of the sample, and the average age at base-
line was 54.306 6.44 years (Table 1 provides a summary of
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criteria were a major neurologic disorder (e.g., head trauma
with loss of consciousness, neoplasms, and seizure disor-
ders), current (i.e., within the previous 12 months) major
psychiatric disease (e.g., major depression, bipolar I, schizo-
phrenia) at both theWRAP visit and theMRI scan, MRI con-
traindications, and abnormal MRI findings (e.g.,
ventriculomegaly). The University of Wisconsin institu-
tional review board approved all study procedures, and
each subject provided signed informed consent before
participation.2.2. Subjective memory measure
As a part of their baseline WRAP visit, the participants
completed a general health questionnaire that included an
item that inquired about SMCs. Specifically, the participants
were asked, “Do you think you have a problem with your
memory?” The participants who responded “yes” (n 5 77)
were considered to have SMCs (i.e., SMC1), and those
who responded “no” (n 5 184) were considered to not
have SMCs (i.e., SMC2).Table 2
Association between SMCs and cortical thickness
Anatomic SMC1 (n 5 77) SMC2 (n 5 184) P value
Hippocampal volume 3930.77 6 384.04 3970.48 6 383.88 .447
Amygdala volume 1572.17 6 195.31 1636.80 6 195.264 .016
Entorhinal 3.37 6 0.26 3.45 6 0.02 .026
Fusiform 2.62 6 0.09 2.65 6 0.01 .044
Parahippocampal 2.69 6 0.26 2.71 6 0.02 .395
Cingulate isthmus 2.51 6 0.18 2.54 6 0.01 .265
Posterior cingulate 2.58 6 0.18 2.62 6 0.01 .043
Precuneus 2.38 6 0.09 2.40 6 0.14 .193
Supramarginal 2.45 6 0.09 2.46 6 0.14 .332
Inferior parietal 2.43 6 0.09 2.46 6 0.14 .036
Abbreviation: SMC, subjective memory complaint.
NOTE. All data presented as estimated mean 6 standard deviation. For
the thickness measures, statistical adjustment was made for age, sex, and
the interval between the cognitive assessment and brain imaging. For the
volume measures, the covariates included age, sex, total intracranial vol-
ume, and interval between cognitive assessment and brain imaging.2.3. Neuroimaging protocol
TheMRI scans were acquired on a GE x750 3.0 T scanner
with an eight-channel phased array head coil (General Elec-
tric, Waukesha, WI). The protocol featured a three-
dimensional T1-weighted inversion recovery-prepared
spoiled gradient-recalled echo volume collected using the
following parameters: inversion time, echo time, and repeti-
tion time of 450 ms, 3.2 ms, and 8.2 ms, respectively; flip
angle of 12; slice thickness 1 mm, no gap; field of view
256; matrix size of 256! 256. The mean interval between
the WRAP visit and the MRI scan was 5.48 6 1.82 years.
Cortical reconstruction and volumetric segmentation was
done using the FreeSurfer software package, version 5.1.0
(available at: http://surfer.nmr.mgh.harvard.edu/). The tech-
nical details of these procedures have been previously
described [23–26]. In brief, the T1-weighted spoiled
gradient-recalled echo acquisitions were skull stripped and
transformed into Talairach space. Next, surface meshes
were created, which are defined by the gray/white matter
boundary (the white matter surface) and the gray/cerebrospi-
nal fluid boundary (the pial surface) [27]. Parcellation and
segmentation were completed using a predefined atlas
[28]. Subcortical volume measures were acquired from the
segmentations, and cortical thickness measurements were
obtained by calculating the distance along a normal vector
from each vertex in the white matter surface to the pial sur-
face. The thickness values at each vertex within a region of
interest (ROI) were averaged to obtain the thickness of the
ROI. A summary measure for each ROI was then derived
by averaging the values from the right and left hemispheres.
Each FreeSurfer output was visually inspected to ensure that
the cortical reconstruction was accurate and without topo-logic defects. Our analyses focused on select ROIs known
to be affected early in the AD cascade, such as the hippocam-
pus and posterior cingulate (Table 2).
2.4. Cognitive assessment
At their baseline WRAP visit, the participants completed
a comprehensive neuropsychological battery that included
psychometric measures spanning the traditional cognitive
domains of memory, attention, executive function, language,
and visuospatial ability. Earlier factor analytic studies
[29,30] of these psychometric measures within the larger
WRAP cohort showed that these tests map onto six
cognitive factors [wN(0,1)]: Immediate Memory, Verbal
Learning & Memory, Working Memory, Speed &
Flexibility, Visuospatial Ability, and Verbal Ability (each
factor’s constituent tests are listed in Table 3). These factor
scores were used in our present evaluation of the association
between SMCs and cognition. In addition to these cognitive
tests, participants also completed the Center for Epidemio-
logical Studies Depression questionnaire (CES-D).
2.5. Statistical analysis
Group differences on baseline demographic measures
were tested using the independent samples t test or chi-
square analyses, as appropriate. We used analyses of covari-
ance (ANCOVA) to test for group differences
(SMC1 versus SMC2) on our a priori ROIs. For the thick-
ness measures, we adjusted for age, sex, and the interval
between the cognitive assessment and brain imaging studies.
For volumetric measures, the covariates included age, sex,
total intracranial volume, and the interval between the cogni-
tive assessment and brain imaging. Similarly, we used an
ANCOVA framework to assess for group differences in the
neuropsychological measures. The covariates included age,
sex, and education. All relevant model assumptions (e.g.,
normality and homogeneity of variance) were evaluated
Table 3
Association between SMCs and objective cognitive performance
Variable
SMC1
(n 5 77)
SMC2
(n 5 184) P value
Immediate Memory 20.170 6 0.97 0.174 6 0.95 .007
RAVLT Trial 1
RAVLT Trial 2
Verbal Learning &
Memory
20.192 6 0.97 0.108 6 0.95 .024
RAVLT Trial 3
RAVLT Trial 4
RAVLT Trial 5
RAVLT Long Delay
Working Memory 20.132 6 1.05 0.126 6 1.09 .068
WAIS Digit Span Forward
WAIS Digit Span
Backward
WAIS Letter-Number
Sequencing
Speed & Flexibility 0.060 6 0.88 0.122 6 0.95 .615
Stroop Color-Word
Trail Making Test A
Trail Making Test B
Visuospatial Ability 0.016 6 0.88 0.216 6 0.95 .096
WASI Block Design
WASI Matrix Reasoning
Benton JLO
Verbal Ability 0.001 6 0.79 0.239 6 0.81 .035
WASI Vocabulary
WASI Similarities
Boston Naming Test
WRAT III—Reading
Abbreviations: RAVLT, Rey Auditory Verbal Learning Test; WAIS,
Wechsler Adult Intelligence Scale; WASI, Wechsler Abbreviated Scale of
Intelligence; JLO, Judgment of Line Orientation; WRAT III, Wide-Range
Achievement Test, 3rd edition.
NOTE. Data presented as estimated mean 6 standard deviation. Statisti-
cal adjustment was made for age, sex, and education.
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formed using SPSS, version 20.0 (IBM Corp., Armonk,
NY). Only findings with a 2-tailed P value  .05 were
considered significant.3. Results
3.1. Background characteristics
The SMC1 and SMC2 groups did not differ signifi-
cantly on age, sex, FH, APOE4 status, education, or global
cognition. Significantly more people with CES-D scores
16 (the established cutpoint for elevated depressive symp-
toms [31]) were in the SMC1 group (n5 11) compared with
the SMC2 group (n 5 5). These results are summarized in
Table 1.
3.2. Association between SMCs and brain structure
The ANCOVA used to examine the group differences in
brain structure revealed that, compared with the SMC2
group, the SMC1 group had a significantly thinner cortex
in the entorhinal, fusiform, posterior cingulate, and inferiorparietal cortices. In addition, the amygdala volume was
significantly lower in the SMC1 group than in the SMC2
group. Although the groups did not differ significantly in
the other brain regions, a consistent trend was observed,
such that the SMC1 group had lower values than the
SMC2 group. These results are listed in Table 2. When
we also adjusted for FH and APOE4 status, the results re-
mained unchanged with the exception that the posterior
cingulate finding became marginally significant (P 5 .085).3.3. Association between SMCs and objective cognitive
function
The results of the comparisons between the SMC1 and
SMC2 groups on objective cognitive measures are listed
in Table 3. The SMC1 individuals had poorer test scores
than those in the SMC2 group in the Immediate Memory,
Verbal Learning & Memory, and Verbal Ability domains.
A trend toward a poorer Working Memory (P 5 .068) and
Visuospatial Ability (P 5 .096) in the SMC1 group was
also observed. However, we noted that—consistent with
this being a cognitively normal cohort—the mean test scores
within the SMC1 group were not lower than 0.2 standard
deviation below the mean for any cognitive domain (the
typical cutpoint for abnormal cognitive test scores was
1.5 standard deviations less than the reference mean).
Just as with the brain structure analysis, we also adjusted
for FH and APOE4 status in the models. The only change
to the initial results was Verbal Ability, which had decreased
to a trend (P 5 .065).3.4. Secondary analyses
Because the study entry criteria excluded persons with a
history of depressive disorders, the observed group differ-
ence on the CES-D was not deemed clinically meaningful.
However, we opted to perform follow-up sensitivity analyses
to determine whether and to what extent our initial findings
were driven by elevated depressive symptoms, given
emerging evidence that SMCs might be linked to depression
[12,32].
We began by running Pearson’s correlations to examine
the associations between our brain/cognitive measures and
the CES-D scores (dichotomized at 16). This was founded
on the statistical premise that, if the CES-D scores were not
associated with the outcomes, the elevated depressive symp-
toms could not be the primary underlying reason for the
observed associations between SMCs and the outcomes
[33]. Next, if any of the brain/cognitivemeasures were found
to correlate significantly with the CES-D, we ran the original
ANCOVA analyses again, including CES-D as an additional
covariate.
The Pearson’s correlations showed that only Verbal Abil-
ity (r 5 20.14, P 5 .024) and entorhinal cortex thickness
(r 5 20.13, P 5 .037) were significantly associated with
the CES-D scores. When the ANCOVAs were refit,
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SMC1 group continued to exhibit lower scores for both Ver-
bal Ability and entorhinal cortex thickness than the SMC2
group. However, these between-group differences became
marginally significant (P5 .076 and P5 .061, respectively).
Of interest, however, the CES-D was not significantly asso-
ciated with either measure [P5 .290 (DR25 .003) and P5
.269 (DR2 5 .005), respectively] in these refitted ANCO-
VAs. Because the essence of our original SMC findings per-
sisted on correction for elevated depressive symptoms, it
appears those initial findings were not primarily driven by
differentials in the depressive symptoms between the 2
groups.
Finally, we repeated these sensitivity analyses using the
CES-D scores obtained from the WRAP visit closest to the
time of the MRI scan (6.84 6 6.12 months), to determine
whether and to what extent our findings were driven by
“MRI-concurrent” depressive symptoms. Pearson’s correla-
tions showed no significant associations (P. .112) between
these MRI-concurrent CES-D scores and our outcome mea-
sures, suggesting that any depressive symptoms at MRI
scanning were unlikely to be the underlying reason for the
observed associations between the presence of SMCs and
the outcomes [33].4. Discussion
In the present study, we found that middle-age individuals
with SMCs have a thinner cortex in AD-vulnerable brain re-
gions, such as the entorhinal, fusiform, inferior parietal, and
posterior cingulate cortices and had a reduced amygdala vol-
ume compared with their peers without SMCs. In addition,
we observed that objective cognitive test scores were
decreased in individuals with SMCs compared with those
without. Specifically, the measures of Immediate Memory,
Verbal Learning & Memory, and Verbal Ability were all
significantly lower in those with SMCs.
An increasing number of studies have investigated struc-
tural brain changes in SMCs [32,34–36]. In one such study,
conducted in a large community-based sample, SMCs were
associated with cross-sectional decrements in hippocampal,
parahippocampal, and amygdalar volumes [35] and longitu-
dinal hippocampal volume loss 4 years later [36]. Similarly,
a study of individuals referred to a memory clinic found that
those with SMCs had a significantly smaller right hippocam-
pal volume than did the controls [32]. Additionally, another
study [34] found that individuals with SMCs had a smaller
hippocampal and parahippocampal volume than did those
without SMCs. Our findings of significant cortical thinning
of AD-relevant cortices complement these volumetric
studies. A previous study [12] had also found that
SMC1 individuals exhibited a lower entorhinal cortex vol-
ume but not a lower hippocampal volume compared with
the SMC2 individuals. This is in accord with the known
topographic progression of neurodegenerative changes in
AD, which starts in the transentorhinal region and thenmoves to the entorhinal cortex, before affecting the hippo-
campus [37–39]. This topographic sequence might explain
why the extent of entorhinal atrophy has been shown to
better identify cognitively normal individuals at risk of
developing AD compared with hippocampal atrophy
[40–42].
Although we did not directly examine the other imaging
biomarkers of AD in the present study, the current hypothet-
ical models of AD pathophysiologic changes suggest that
brain structure changes occur later in the AD cascade than
alterations in amyloid-b and glucose metabolism [43].
Therefore, our observed group differences in brain structure
would suggest that cerebral amyloidosis and/or hypometab-
olism in AD-related brain regions might be detectable in in-
dividuals with SMCs. An increasing number of studies have
reported evidence for such disease-related changes
[5,7,15,32]. Perrotin et al [15] found that individuals with
SMCs had increased fibrillary amyloid deposition in the
right posterior cingulate and precuneus, and another study
[32] observed hypometabolism in the right parahippocampal
gyrus, right hippocampus, and bilateral precuneus in older
adults with SMCs. These findings, combined with the find-
ings from our study, provide new neuroimaging evidence
of cortical thinning in AD-vulnerable brain regions, adds
to the hypothesis that individuals with SMCs might repre-
sent a population at increased risk of eventual progression
to probable AD [43–47].
Investigations of the link between SMCs and objective
cognitive performance are an active area of research, and
the emerging evidence has been heterogeneous
[4,5,12,32,48]. Congruent with our study, Amariglio et al
[5] found SMCs were associated with decreased episodic
and working memory. Similarly, Scheef et al [32] found a
decline in episodic and immediate verbal memory in a pop-
ulation with SMCs. Another longitudinal study has also pro-
vided evidence for a decline in the measures of working
memory and perceptual motor skills in individuals with
SMCs [4]. Our observation of comparatively decreased per-
formance in Immediate Memory, Verbal Learning & Mem-
ory, and Verbal Ability in individuals with SMCs is in
accordance with the findings from these previous studies.
Similar to medial temporal lobe structural alterations,
impairment in episodic memory is an early feature of AD
[49]. Therefore, our finding of concomitant decreases in
episodic memory and mesial temporal cortical thickness in
our SMC1 participants increases the possibility that these
individuals might be in the very early stages of the AD
cascade. Because the WRAP is an ongoing study, we will
be well positioned to investigate the long-term prognostic
utility of early subjective complaints.
We observed no significant group differences in APOE4
status, FH, age, education, or sex, indicating that those
with these risk factors for AD are not any more likely to
report SMCs in midlife than those without these risk factors.
This is in agreement with most studies of SMCs
[12,15,32,48]. However, the absence of a FH differential
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with a FH are typically aware they harbor this risk factor,
which is not always the case for other risk factors, such as
APOE4 status. This awareness, and the experience of
observing the disease course in their affected relatives,
often leads to a heightened sensitivity to what might
otherwise be normal variability in cognitive functioning
[50,51]. Therefore, if SMCs were merely a symptom of a
“worried well” population, one would have expected that
persons with a FH would disproportionately endorse
subjective memory failures [52]. The absence of such an as-
sociation in our sample suggests that, at least in some con-
texts, a simple inquiry into SMCs might have clinical
validity for identifying the subset of cognitively normal per-
sons who might truly be experiencing objective cognitive
difficulties and associated brain changes and thus have a
greater risk of future progression to AD.
Our observation of greater depressive symptoms in the
SMC1 group parallels reports from other investigators
[7,12,32,34,53]. A recent study by Steinberg et al [53] found
that scores on a questionnaire pertaining to SMCs were asso-
ciated with measures of depressive symptoms. Additionally,
other investigators [12,32] have found individuals with
SMCs to have significantly higher scores on measures of
depression compared with controls. In both these latter
studies, differences between the SMC2 and
SMC1 groups for gray matter volume, cerebral glucose
metabolism, and cognitive performance persisted even
after adjustment for depressive symptoms. Similarly,
although we found the CES-D scores to bivariately correlate
with two of our outcome measures (Verbal Ability and ento-
rhinal cortex thickness), when we included the CES-D
scores in the original multivariable statistical model, it failed
to be associated with either of these measures, and the
essence of our original SMC findings persisted. When this
negative CES-D finding is placed in the context of our
study’s entry criteria, which excluded persons with major
depression and other major psychiatric disorders, it appears
rather improbable that the memory complaints were driven
by clinical depression in our study. Although some evidence
has shown that mid-to-late-life depressive symptoms are
associated with cortical thinning in the parietal and temporal
regions [54] and might even be a prodrome for dementing
disorders [55]. It would be of future interest to determine
whether greater depressive symptoms at baseline are associ-
ated with prospective changes in brain health and cognition
within our cohort [56].
Our study had some limitations. Although the cross-
sectional nature of our study has provided insight into the
initial brain and cognitive changes that might be differen-
tially occurring in middle-age individuals with SMCs, longi-
tudinal studies are needed for a full understanding of these
initial findings. Given that the WRAP is ongoing, we will
have the data to determine whether asymptomatic individ-
uals with SMCs are more likely to transition to the symptom-
atic stages of the AD cascade. Also, the WRAP cohort ispredominantly composed of highly educated, non-Hispanic
white individuals. Therefore, it is not known whether our
measure of SMCs would be similarly associated with brain
structure and objective cognition in a more heterogeneous
middle-age sample. Additionally, a single question about
subjective complaints, such as that used in the present study,
might be vulnerable to temporal instability and might fail to
adequately capture the underlying complexity that these
complaints represent. Extensive precedent is present in the
published data, however, for such single-item measures of
subjective complaints, such as was documented in the recent
white paper from the Subjective Cognitive Decline Initiative
Working Group [1]. A major goal of the working group is to
institute common standards for the burgeoning SMC field.
These common standards, once established, will help guide
future work, including our own, on SMCs.
In conclusion, our results have indicated that at-risk,
cognitively normal, middle-age individuals with SMCs
exhibit cortical thinning in the brain regions affected by
AD and poorer objective scores—albeit within normal
limits—on memory tests. These results add to the
increasing body of published data, suggesting that individ-
uals with SMCs might be at increased risk of progression
to AD. A simple question about subjective memory, such
as the one asked in the present study, could be easily incor-
porated into busy clinical practices, with potential to be
useful for the early identification of at-risk older adults,
especially when used in conjunction with other pertinent
health and clinical information. Such individuals might
then be potential candidates for clinical trials investigating
disease-modifying interventions for AD.Acknowledgments
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1. Systematic review: We searched PubMed using the
terms: “subjective memory complaint,” “SMC,”
“SMI,” “subjective cognitive impairment,” “subjec-
tive memory impairment,” “subjective cognitive
complaints” and “Alzheimer’s disease,” or “demen-
tia.”
2. Interpretation: Early detection of individuals at
increased risk of developing dementia is of major sci-
entific and clinical interest. Our study finds that
middle-age, asymptomatic, persons with SMCs
have a thinner cortex in brain regions affected by
Alzheimer’s disease compared with persons without
such subjective complaints. SMCs were also asso-
ciated with objective cognitive performance in our
cohort. These findings support the use of SMCs as a
potential method for identifying cognitively normal
persons with subtle brain and cognitive changes that
might be indicative of incipient Alzheimer’s disease.
3. Future directions: Continued follow-up of our cohort
will allow us to determine whether asymptomatic
individuals with SMCs will transition into symp-
tomatic stages of the AD cascade.
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